Top Page
Verici Dx Plc
(LSE:VRCI)
Verici Dx Plc (VRCI) vs. iShares MSCI United Kingdom ETF (EWC)
Verici Dx Plc Business Overview & Revenue Model
Verici Dx Plc Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.34M | 1.01M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.34M | 1.01M | 0.00 | 0.00 | 0.00 |
| EBITDA | -5.15M | -7.88M | -10.50M | -7.15M | -2.10M |
| Net Income | -5.87M | -8.73M | -11.36M | -8.33M | -7.10M |
Balance Sheet | |||||
| Total Assets | 7.49M | 7.44M | 14.30M | 13.79M | 20.31M |
| Cash, Cash Equivalents and Short-Term Investments | 4.06M | 2.65M | 9.80M | 10.34M | 17.75M |
| Total Debt | 371.00K | 540.00K | 156.00K | 0.00 | 73.55K |
| Total Liabilities | 2.23M | 3.88M | 2.80M | 1.80M | 681.89K |
| Stockholders Equity | 5.26M | 3.56M | 11.51M | 11.98M | 19.62M |
Cash Flow | |||||
| Free Cash Flow | -6.21M | -7.39M | -11.38M | -7.30M | -1.32M |
| Operating Cash Flow | -6.02M | -7.16M | -10.07M | -6.34M | -1.28M |
| Investing Cash Flow | 61.00K | -231.00K | -1.31M | -965.86K | -237.16K |
| Financing Cash Flow | 7.32M | -27.00K | 12.67M | -73.55K | 26.75M |
Verici Dx Plc Technical Analysis
Verici Dx Plc Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £11.62M | ― | -62.83% | ― | 27.60% | 1.35% | |
52 Neutral | £3.09M | ― | -46.41% | ― | -64.18% | 12.05% | |
51 Neutral | $7.83B | -0.18 | -40.10% | 2.29% | 21.46% | -2.03% | |
51 Neutral | £4.84M | ― | -321.90% | ― | 125.37% | 22.47% | |
46 Neutral | £4.02M | ― | -367.05% | ― | 25.05% | 65.30% | |
45 Neutral | £7.95M | ― | -130.73% | ― | 226.45% | 53.51% | |
43 Neutral | £8.86M | ― | ― | -2.80% | -38.55% |
Verici Dx Plc Corporate Events
Verici Dx Plc announced the publication of several abstracts related to its Tutivia™ test ahead of the World Transplant Congress 2025. These abstracts highlight the test’s role in addressing unmet needs in transplant patient care, including managing BK nephropathy and obesity-related complications. The real-world evidence from multiple transplant centers underscores the test’s utility and supports its growing adoption, which is further bolstered by Medicare coverage.
Verici Dx Plc announced the successful completion of its WRAP Retail Offer, raising approximately £0.43 million at an issue price of 0.5 pence per share. This fundraising, combined with previous placements and subscriptions, has generated total gross proceeds of approximately £6.35 million, extending the company’s cash runway into the second half of 2026. The new shares are expected to be admitted to trading on AIM by 30 July 2025, increasing the company’s total ordinary share capital to over 1.5 billion shares. This financial boost is likely to enhance Verici Dx’s operational capabilities and strengthen its position in the clinical diagnostics market.
Verici Dx Plc has announced a retail offer to raise up to £500,000 through the issuance of new ordinary shares as part of its fundraising efforts. This follows a successful Placing and Subscription that raised approximately £5.92 million. The retail offer is open to eligible investors in the UK and aims to involve both new and existing shareholders. The proceeds from this offer will be used in the same manner as the previous fundraising, with the new shares expected to commence trading on AIM by the end of July 2025.
Verici Dx Plc has successfully raised approximately £5.92 million through an oversubscribed placing and subscription, with significant participation from existing and new investors. The funds will be used to accelerate the commercial growth and scale-up of Tutivia™, enhancing patient outcomes for kidney transplant patients in the US. The company’s strategic fundraising efforts highlight its commitment to expanding its market presence and improving diagnostic accuracy in the organ transplant sector.
Verici Dx Plc has announced a proposed equity fundraising to raise at least £5 million to support the commercial scale-up of its kidney transplant diagnostic tests. The fundraising involves a placing of new shares, a subscription by a US investor, and a retail offer, with the proceeds aimed at accelerating the company’s growth and enhancing its market position in transplant diagnostics.
Verici Dx reported record revenues of $3.3 million for 2024, driven by a commercial contract with Thermo Fisher for its PTRA test. The company achieved several operational milestones, including securing Medicare coverage for its Tutivia™ assay and receiving CLIA certification, which enhances its testing capabilities across the US. Despite financial challenges, including a need for additional funding by July 2025, Verici Dx is optimistic about its future growth, particularly in the post-transplant market, which is valued at approximately $900 million. The company aims to expand its market presence by addressing unmet needs in areas like delayed graft function and BK nephropathy.
Verici Dx Plc announced plans to raise funds through an equity fundraising to extend its cash runway and support the commercial growth of its Tutivia™ diagnostic test, following the recent Medicare coverage approval. The company aims to achieve $3.2 million in Tutivia™ revenues for FY 2025, and the fundraising will involve a placing and a retail offer for existing shareholders, with further updates expected by the end of June.
Verici Dx Plc announced that all resolutions were passed at its recent General Meeting, with overwhelming support from shareholders. This development signifies strong backing for the company’s strategic decisions, potentially enhancing its operational capabilities and reinforcing its position in the organ transplant diagnostics sector.
Verici Dx plc has published a Circular seeking shareholder approval to issue new Ordinary Shares on a non-pre-emptive basis, as part of a proposed fundraising initiative. This fundraising aims to accelerate the company’s commercial growth and support the scaling up of revenues for its Tutivia™ product, following the recent securing of Medicare Coverage. The company anticipates that existing allotment authorities will be insufficient for the proposed fundraising, which is expected to involve a placing with institutional and other investors. The size and structure of the fundraising are yet to be determined, and further updates will be provided in due course.
Verici Dx Plc has announced a change in the voting rights structure, with Maven Capital Partners UK LLP now holding a 5.702% stake in the company. This adjustment in voting rights reflects Maven’s increased influence in Verici Dx’s strategic decisions, potentially impacting the company’s future direction and stakeholder interests.